Comparative pharmacology of oral fluoropyrimidines: A focus on pharmacokinetics, pharmacodynamics and pharmacomodulation

British Journal of Cancer

Volumn 91, Issue 4, 2004, Pages 613-617

  Milano, G ^a   Ferrero, J M ^a   Francois E ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Capecitabine; Oral chemotherapy; UFT

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; 5 ETHYNYLURACIL; CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; EMITEFUR; FLUOROPYRIMIDINE; FLUOROURACIL; N 4 PENTYLOXYCARBONYL 5' DEOXY 5 FLUOROCYTIDINE; ORZEL; UFT; UNCLASSIFIED DRUG;

CIRCULATION; CLINICAL PROTOCOL; COMPARATIVE STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; ENZYME INHIBITION; METABOLIC ACTIVATION; PREDICTION; PRIORITY JOURNAL; SHORT SURVEY;

EID: 4344715339     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601973     Document Type: Short Survey

References (42)

1. Advanced Colorectal Cancer Meta-analysis Project (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: 896-903
2. Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin J, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton P, Ames MM, Erlichman C (2002) Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumours. J Clin Oncol 20: 1683-1691
3. Baker SD, Diasio RB, O'Reilly S, Sol Lucas V, Khor SP, Sartorius SE, Donehower RC, Grochow LB, Spector T, Hohneker JA, Rowinsky E (2000) Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. J Clin Oncol 18: 915-926
4. Cassidy J, Twelves C, Cameron D, Steward W, O'Byrne K, Jodrell D, Banken L, Goggin T, Jones D, Roos B, Bush E, Weidekamm E, Reigner B (1999) Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol 44: 453-460
5. Codacci-Pisanelli G, Van der Wilt CL, Pinedo HM, Franchi F, Noordhuiso P, Braakhuis Bj, van Laar JA, Peters GJ (1995) Antitumour activity toxicity and inhibition of thymidylate synthase of prolonged administration of 5-fluorouracil in mice. Eur J Cancer 31: 1517-1525
6. Damle B, Ravandi F, Kaul S, Sonnichsen D, Ferreira I, Brooks D, Stewart D, Alberts D, Pazdur R (2001) Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients. Clin Cancer Res 7: 517-523
7. Diasio RB (1999) Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines. Drugs 58: 119-126
8. Endo M, Miwa M, Eda H, Ura M, Tanimura H, Ishikawa T, Miyazaki-Nose T, Hattori K, Shimma N, Yamada-Okabe H, Ishitsuka H (2003) Augmentation of the antitumour activity of capecitabine by a tumour selective dihydropyrimidine dehydrogenase inhibitor, R00094889. Int J Cancer 106: 799-805
9. Grem JL (1996) 5-Fluoropyrimidines. In Cancer Chemotherapy and Biotherapy, Chabner BA, Longo DL (eds) pp 149-212, Philadelphia, PA: Lipppincott-Raven
10. Hattori K, Kohchi Y, Oikawa N, Suda H, Ura M, Ishikawa T, Miwa M, Endoh M, Eda H, Tnaimura H, Kawashima A, Horii I, Ishitsuka H, Shimma N (2003) Design and synthesis of the tumour-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine. Bioorg Med Chem Lett 13: 867-872
11. Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T, Shirasaka T (1999) Pharmacokinetic study of S-1, a novel oral fluorouracil antitumour drug. Clin Cancer Res 5: 2000-2005
12. 1-(2′- tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res 4: 2085-2088
13. Ho DH, Covington W, Brown N, Lin SN, Pazdur R, Huo YY, Creaven PJ, Rustum YM, Meropol NJ, Lassere Y, Kuritani J, Hayadawa T (2000) Oral uracil and ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. Cancer Chemother Pharmacol 46: 351-356
14. Humerickhouse RA, Dolan ME, Haraf DJ, Brockstein B, Stenson K, Kies M, Sulzen L, Ratain MJ, Vokes EE (1999) Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin Cancer Res 5: 291-298
15. Ichikura T, Tomimatsu S, Okusa Y, Yahara T, Uefuji K, Tamakuma S (1996) Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low-dose leucovorin for patients with gastric cancer. Cancer Chemother Pharmacol 38: 401-405
16. Ikeda K, Yoshisue K, Matsushima E, Nagayama S, Kobayashi K, Tyson CA, Chiba K, Kawaguchi Y (2000) Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin Cancer Res 6: 4409-4415
17. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H (1998) Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumours in human cancer xenografts. Cancer Res 58: 685-690
18. Ichikawa W, Uetake H, Shirota Y, Yamada H, Nishi N, Nihei Z, Sugihara K, Hirayama R (2003) Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumours as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 9: 786-791
19. Mader RM, Schrolnberger C, Rizovski B, Brunner M, Wenzel C, Locker G, Fichler HG, Mueller M, Steger GG (2003) Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer. B J Cancer 88: 782-787
20. Meropol NJ, Sonnichsen DS, Birkhofer M, Ferreira I, Noel D (1999) Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer. Cancer Chemother Pharmacol 43: 221-226
21. Muggia FM, Wu X, Spicer D, Groshen S, Jeffers S, Leichman G, Leichman L, Chan KK (1996) Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil. Clin Cancer Res 2: 1461-1467
22. Nemunaitis J, Eager R, Twaddell T, Corey A, Sekar K, Tkaczuk K, Thompson J, Hoff PM, Pazdur R (2000) Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumours. J Clin Oncol 18: 3423-3434
23. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812-2823
24. Peters GJ, Noordhuis P, Van Kuilenburg AB, Schornagel JH, Gall H, Turner SL, Swart MS, Voom D, Van Gennip AH, Wanders J, Holwerda U, Smid K, Giaccone G, Fumoleau P, Van Groeningen CJ (2003) Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumours. Cancer Chemother Pharmacol 52: 1-12
25. Petit E, Milano G, Levi F, Thyss A, Bailleul F, Schneider M (1988) Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five day continuous venous infusion at a constant rate in cancer patients. Cancer Res 48: 1976-1979
26. Pivot X, Chamorey E, Guardiola E, Magn N, Thyss A, Otto J, Giroux B, Mouri Z, Schneideer M, Milano G (2003) Phase 1 and pharmacokinetic study of the association of capecitabine - cisplatin in head and neck cancer patients. Ann Oncol 14: 1578-1586
27. Poole C, Gardiner J, Twelves C, Johnston P, Harper P, Cassidy J, Monhouse J, Banken L, Weidekamm E, Reigner B (2002) Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 49: 225-234
28. Reigner B, Verweij J, Dirix L, Cassidy J, Twelves C, Allman D, Weidekamm E, Roos B, Banken L, Utoh M, Osterwalder B (1998) Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 4: 941-948
29. Reigner B, Blesch K, Weidekamm E (2001) Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40: 85-104
30. Sadahiro S, Suzuki T, Kameya T, Iwase H, Tajima T, Makuuchi H (2001) A pharmacological study of the weekday-on/weekend-off oral UFT schedule in colorectal cancer patients. Cancer Chemother Pharmacol 47: 457-460
31. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4: 1013-1019
32. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H (1999) X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (xeloda) in human cancer xenografts. Clin Cancer Res 5: 2948-2953
33. Shepard DR, Mani S, Kastrissios H, Learned-Coughlin S, Smith D, Ertel P, Magnum S, Janish L, Fleming GF, Schilsky RL, Ratain MJ (2002) Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil. Cancer Chemother Pharmacol 49: 398-402
34. Shimasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumour selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557
35. Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B (2000) Preferential activation of capecitabine in tumour following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45: 291-297
36. Tachibana M, Yasuda N, Yoshimatsu M, Nishimura H, Mizukoshi O (1987) UFT for head and neck cancers: its tissue concentrations and effects on lymphocyte subpopulations. Cancer Chemother Pharmacol 19: 65-68
37. Tatsumi K, Yamauchi T, Kiyono D, Kishi K, Yanagihara Y, Imaoka T, Kawaguchi T, Kubo M (1993) 3-Cyano-2,6-dihydroxypyridine (CNDP), a new potent inhibitor of dihydrouracil dehydrogenase. J Biochem 114: 912-918
38. Tsukamoto Y, Kato Y, Ura M, Horii I, Ishituska H, Kusuhara H, Sugiyama Y (2001) A physiologically-based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumour-selective accumulation of 5-FU. Pharm Res 18: 1190-1202
39. Twelves C, Glynne-Jones R, Cassidy J, Schüller J, Goggin T, Roos B, Banken L, Utoh M, Weidekamm E, Reigner B (1999) Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 5: 1696-1702
40. Urien S, Fumoleau P, Campone M, Kerbrat P, Bonneterre J, Fargeot P, Deporte-Fety R (2003) Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer. Cancer Chemother Pharmacol 52: 99-107
41. Van Cutsem E, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, Cassidy J, Dirix L, Twelves C, Allman D, Seitz JF, Schölmerich J, Burger HU, Verweij J (2000) Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 18: 1337-1345
42. Van Groeningen CJ, Peters GJ, Schornagel JH, Gall H, Noordhuis P, de Vries MJ, Turner SL, Swart MS, Pinedo HM, Hanauske AR, Giaccone G (2000) Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumours. J Clin Oncol 18: 2772-2779